Royalty Report: Drugs, Vaccine, Drug Discovery – Collection: 304223


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Vaccine
  • Drug Discovery
  • Cancer
  • Nanoparticles

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 304223

License Grant
University granted to the Company an exclusive license for certain inventions and technologies related to nanoparticles useful as vaccines.
License Property
The University has developed certain inventions and technology related to nanoparticles.

The Inventions and Technologies licensed relate to the ABBIE patent estate that includes patent families.  One such family is titled “Novel Nanoparticle–Based Vaccine Targeting Cancer/Testis Antigens (CTA) and its’ Use in Solid and Hematological Malignancies”.  The use and methods for a vaccine composition comprising of particles comprising nanoparticles, microparticles or a mixture thereof.

ABBIE is a non-viral gene editing mechanism to insert the target DNA template information into the T cell genome at a precise, predetermined locus. ABBIE allows the creation of the plasmid (“glue”) that goes through the membrane to the nucleus and inserts the genome template into the T cells so that they could express the CAR T protein and possibly other accessory proteins while possibly eliminating unwanted inhibitory proteins.

Field of Use
Licensee is a target discovery and gene editing company utilizing artificial intelligence and their proprietary neural network platform with a therapeutic focus on immuno-oncology.

The license granted is for the inventions and technologies for the use of oral vaccines for any diseases, including, without limitation, any form of cancer.

IPSCIO Record ID: 356264

License Grant
University grants an exclusive license under the patent rights to make, use, offer for sale, import, and sell licensed products and licensed services, and to practice Licensed method, in the Licensed Field of use in the Licensed Territory.
License Property
University has an assignment of the Escherichia Coli K12 to deliver protein to the macrophage cytosol.
Field of Use
The Licensee uses its proprietary platform technology called AnTigen Lead Acquisition System ('ATLAS') to discover and develop novel vaccine candidates. The ATLAS proprietary technology platform mimics the human immune response in the laboratory, potentially improving the effectiveness of vaccine discovery and drastically reducing the time needed to create promising vaccines.

IPSCIO Record ID: 305790

License Grant
Under this license, Licensee received an exclusive, worldwide, royalty-bearing, sublicenseable license under Licensor’s patents and know-how relating to cell-free expression of proteins to (i) research, develop, use, sell, offer for sale, export, import and otherwise exploit specified vaccine compositions, such rights being sublicensable, for the treatment or prophylaxis of infectious diseases, excluding cancer vaccines, and (ii) manufacture, or have manufactured by an approved contract manufacturing organization, such vaccine compositions from extracts supplied by Licensor pursuant to the Licensor Supply Agreement.  Licensee is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize the vaccine compositions.
License Property
The vaccine compositions used the Licensors proprietary cell-free protein expression technology, known as XpressCF which utilizes extracts derived from strains of E. Coli.

Licensor is a clinical stage, publicly-traded drug discovery, development and manufacturing company using precise protein engineering and rational design (enabled by Licensors proprietary XpressCF platform technology) to advance next-generation oncology therapeutics.

The primary invention underpinning the XpressCF platform was the creation of engineered E.coli-derived proprietary extracts containing fully functional oxidative phosphorylation machinery in inverted membrane vesicles and orthogonal tRNA capable of catalyzing nnAA incorporation. This innovation enables the Extract to regenerate high energy phosphates required for protein translation and nnAA incorporation, reducing production cost and permitting the use of industrial sized reaction vessels and longer manufacturing run times than previously thought possible. The XpressCF system routinely produces g/L of complex proteins in 8-10 hours and scales linearly from bench to large-scale GMP production. The protein of interest is produced at high yield and the absence of cellular debris combine to simplify downstream purification, further enhancing production efficiency.

Field of Use
The XpressCF platform is used in the field of vaccines to address infectious diseases in both human and animal use.

XpressCFâ„¢, an industrialized cell-free protein synthesis platform, for the vaccine field allowing (1) site-specific conjugation; (2) production of complex antigens in more optimal conformation; and (3) speed, flexibility and scalability of the discovery engine.

The XpressCF platform overcomes these significant limitations by separating the precise cellular machinery required for transcription, translation, and energy production into an E.coli-derived mixture, or Extract capable of continuous oxidative phosphorylation.

Licensee is a next-generation vaccine company whose cell-free protein synthesis platform enables the design and production of optimized protein carriers and antigens, the critical building blocks of vaccines.

IPSCIO Record ID: 345200

License Grant
In the original agreement, therapeutic and prophylactic vaccines were specifically excluded from the definition of Therapeutic Licensed Product under the License Agreement.

For clarification, the University has the right to grant exclusive licenses to third parties under the Patent Rights to develop, make, have made, use, sell, offer to sell, lease, and import any product that is solely a therapeutic or prophylactic vaccine and to develop and perform Licensed Processes solely to develop, make, have made, use, sell, offer to sell, lease and import any product that is solely a therapeutic or prophylactic vaccine.

License Grants, of the License Agreement shall be amended to read in its entirety as follows
The University grants to Company a license under the Patent Rights to develop, make, have made, use, sell, offer to sell, lease, and import Therapeutic Licensed Products and Diagnostic Licensed Products  in the Disease Field; develop, make, have made, use, sell, offer to sell, lease, and import Reagent Licensed Products; and develop and perform Licensed Processes except, solely, to develop, make, have made, use, sell, offer to sell, lease, and import any product that is solely a therapeutic or prophylactic vaccine, unless earlier terminated per the terms of this Agreement.

In order to establish an exclusive period for Company and University agrees that it shall not grant any other license under the Patent Rights (except University Sub 100Nm Biodegradable Polymer Spheres Capable Of Releasing Nucleic Acids) to develop, make, have made, use, sell, offer to sell, lease or import Therapeutic Licensed Products or Diagnostic Licensed Products in the Disease Fields in the Territory during the Term, or to develop or perform Licensed Processes, other than solely to develop, make, have made, use, sell, offer to sell, lease, or import any product that is solely a therapeutic or prophylactic vaccine, in the Disease Fields in the Territory during the Term, unless earlier terminated per the terms of this Agreement.

License Property
University is the owner or joint owner of certain Patent Rights relating to Formulation of Polymeric Particles for Prostate Cancer Targeting, and, Cancer Cell Targeting Using Nanoparticles.
Field of Use
The original agreement states Disease Field shall mean a field specific to a class of diseases. Examples include, but are not limited to cancer;  cardiovascular disease (atherosclerosis, congestive heart failure, etc.); immune/inflammatory disorders (rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, etc.); respiratory diseases (asthma, emphysema, central obstructive pulmonary disease, etc.); central nervous system disorders (Alzheimers disease, Parkinsons, etc.); and metabolic diseases (obesity, diabetes, etc.).
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.